AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
ABCellera（納斯達克股票代碼：ABCL）和Biogen Inc.（納斯達克股票代碼：BIIB）已達成戰略合作，以發現一種用於新靶標的抗體，該靶標能夠將生物療法輸送到大腦以適應神經科學的適應症。
"Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience," said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. "We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions."
Abcellera合作高級副總裁Murray McCutcheon博士說：“通過血腦屏障輸送生物製劑是神經科學中最重要、最長期存在的問題之一。”“我們很高興與Biogen合作開展這項創新計劃，該計劃有可能開啓多種治療神經系統疾病的新方法。”
Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone payments should the research programs achieve certain research, developmental and regulatory milestones. AbCellera is also eligible to receive potential royalties on future net sales of products that result from the collaboration.
根據協議條款，如果研究項目實現某些研究、開發和監管里程碑，Abcellera將獲得預付款，並且有資格獲得額外的里程碑付款。AbCellera還有資格從合作產生的產品未來淨銷售額中獲得潛在的特許權使用費。
譯文內容由第三人軟體翻譯。